Parkinsonism & related disorders最新文献

英文中文

Breath hydrogen levels in patients with Parkinson's disease: A pilot cross-sectional study

IF 3.1 3区医学 Q2 CLINICAL NEUROLOGY

Parkinsonism & related disorders

Pub Date : 2025-02-27 DOI: 10.1016/j.parkreldis.2025.107353

Sonja Baltic , Nikola Todorovic , Sanela Popovic , Vladimir Galic , Marija Semnic , Sergej M. Ostojic

引用次数: 0

Paroxysmal nocturnal dystonia in DNM1L-related syndrome

IF 3.1 3区医学 Q2 CLINICAL NEUROLOGY

Parkinsonism & related disorders

Pub Date : 2025-02-23 DOI: 10.1016/j.parkreldis.2025.107351

Paula Stretavská , Ján Necpál , Eva Trúsiková , Katarína Okáľová , Sabina Latka , Robert Jech , Michael Zech

引用次数: 0

A pilot interventional study on feasibility and effectiveness of the CUE1 device in Parkinson's disease

IF 3.1 3区医学 Q2 CLINICAL NEUROLOGY

Parkinsonism & related disorders

Pub Date : 2025-02-22 DOI: 10.1016/j.parkreldis.2025.107349

Viktoria Azoidou , Kira Rowsell , Ellen Camboe , Kamalesh C. Dey , Alexandra Zirra , Corrine Quah , Thomas Boyle , David Gallagher , Alastair J. Noyce , Cristina Simonet

Introduction

Current treatments for patients with Parkinson's disease (PwP) can fail to address gait disturbance and falls, which in turn affect quality of life (QoL). The CUE1 device delivers cueing with vibrotactile stimulation showing potential to alleviate motor symptoms and reduce falls based on preliminary user testing results. This study aimed to evaluate the feasibility, safety, and tolerability of CUE1 and its effect on motor and non-motor symptoms in PwP.

Methods

PwP used the CUE1 for 9-weeks and were assessed at week 0, 3, 6, and 9 on MDS-UPDRS Part-III, Timed Up and Go (TUG), TUG with dual task (DT), and Functional Gait Assessment (FGA). Patients-reported outcomes were assessed through MDS-UPDRS Part-I, Part-II, and Part-IV.

Results

Ten PwP (5 females, age range: 46–80; disease duration: 3–9 years) completed the CUE1 intervention with 100 % compliance and no adverse events. CUE1 comfort and usability were rated highly (80 %). Immediate CUE1 effect was observed on MDS-UPDRS Part-III (45.40 ± 12.22 vs 39.60 ± 11.74, p = 0.008), TUG (11.53 ± 1.92 vs 11.08 ± 1.94, p = 0.022), TUG DT (18.57 ± 5.75 vs 17.61 ± 6.28, p = 0.037) and FGA (16.40 ± 3.86 vs 18.60 ± 3.92, p = 0.007). Cumulative effect was noted on MDS-UPDRS-III (45.40 ± 12.22 vs 27.80 ± 12.32, p = 0.005), FGA (18.60 ± 3.92 vs 23.10 ± 2.85, p < 0.001), TUG DT (18.57 ± 5.75 vs 13.58 ± 7.05, p = 0.031), MDS-UPDRS Part-I (18.60 ± 6.75 vs 12.20 ± 3.68, p = 0.011), MDS-UPDRS Part-II (17.30 ± 7.29 vs 11.90 ± 8.67, p = 0.002), and MDS-UPDRS Part-IV(7.50 ± 3.75 vs 3.40 ± 2.95, p = 0.003).

Conclusion

In this unblinded, feasibility study, cueing with vibrotactile stimulation delivered via the CUE1 technology appeared to be a feasible, safe and well tolerated intervention for PwP improving motor and non-motor features.

{"title":"A pilot interventional study on feasibility and effectiveness of the CUE1 device in Parkinson's disease","authors":"Viktoria Azoidou , Kira Rowsell , Ellen Camboe , Kamalesh C. Dey , Alexandra Zirra , Corrine Quah , Thomas Boyle , David Gallagher , Alastair J. Noyce , Cristina Simonet","doi":"10.1016/j.parkreldis.2025.107349","DOIUrl":"10.1016/j.parkreldis.2025.107349","url":null,"abstract":"<div><h3>Introduction</h3><div>Current treatments for patients with Parkinson's disease (PwP) can fail to address gait disturbance and falls, which in turn affect quality of life (QoL). The CUE1 device delivers cueing with vibrotactile stimulation showing potential to alleviate motor symptoms and reduce falls based on preliminary user testing results. This study aimed to evaluate the feasibility, safety, and tolerability of CUE1 and its effect on motor and non-motor symptoms in PwP.</div></div><div><h3>Methods</h3><div>PwP used the CUE1 for 9-weeks and were assessed at week 0, 3, 6, and 9 on MDS-UPDRS Part-III, Timed Up and Go (TUG), TUG with dual task (DT), and Functional Gait Assessment (FGA). Patients-reported outcomes were assessed through MDS-UPDRS Part-I, Part-II, and Part-IV.</div></div><div><h3>Results</h3><div>Ten PwP (5 females, age range: 46–80; disease duration: 3–9 years) completed the CUE1 intervention with 100 % compliance and no adverse events. CUE1 comfort and usability were rated highly (80 %). Immediate CUE1 effect was observed on MDS-UPDRS Part-III (45.40 ± 12.22 vs 39.60 ± 11.74, p = 0.008), TUG (11.53 ± 1.92 vs 11.08 ± 1.94, p = 0.022), TUG DT (18.57 ± 5.75 vs 17.61 ± 6.28, p = 0.037) and FGA (16.40 ± 3.86 vs 18.60 ± 3.92, p = 0.007). Cumulative effect was noted on MDS-UPDRS-III (45.40 ± 12.22 vs 27.80 ± 12.32, p = 0.005), FGA (18.60 ± 3.92 vs 23.10 ± 2.85, p < 0.001), TUG DT (18.57 ± 5.75 vs 13.58 ± 7.05, p = 0.031), MDS-UPDRS Part-I (18.60 ± 6.75 vs 12.20 ± 3.68, p = 0.011), MDS-UPDRS Part-II (17.30 ± 7.29 vs 11.90 ± 8.67, p = 0.002), and MDS-UPDRS Part-IV(7.50 ± 3.75 vs 3.40 ± 2.95, p = 0.003).</div></div><div><h3>Conclusion</h3><div>In this unblinded, feasibility study, cueing with vibrotactile stimulation delivered via the CUE1 technology appeared to be a feasible, safe and well tolerated intervention for PwP improving motor and non-motor features.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"133 ","pages":"Article 107349"},"PeriodicalIF":3.1,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143488477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Closing the loop in DBS: A data-driven approach.

IF 3.1 3区医学 Q2 CLINICAL NEUROLOGY

Parkinsonism & related disorders

Pub Date : 2025-02-21 DOI: 10.1016/j.parkreldis.2025.107348

Prerana Acharyya, Kerry W Daley, Jin Woo Choi, Kevin B Wilkins, Shreesh Karjagi, Chuyi Cui, Gang Seo, Annie K Abay, Helen M Bronte-Stewart

Deep brain stimulation (DBS) has transformed the treatment of movement disorders like Parkinson's Disease (PD). Innovations in DBS technology and experimentation have fostered adaptive DBS (aDBS), which employs a closed-loop system that senses physiological biomarkers to inform precise neuromodulation and personalized therapy. This review analyzes several promising advances in aDBS, including biomarker detection, control policies, mechanisms of efficacy, and a data-driven approach using artificial intelligence to decode motor states from neural signals. Investigations into data-driven approaches have expanded biomarker detection beyond subcortical beta oscillations, leveraging other neural and kinematic signals. Future aDBS systems that accommodate multi-modal inputs have the potential to bolster therapeutic efficacy and address symptoms not addressed by beta-driven aDBS. Continuing investigation is necessary to address existing technical and computational challenges for further clinical translation.

引用次数: 0

Are we ready for automated deep brain stimulation programming?

IF 3.1 3区医学 Q2 CLINICAL NEUROLOGY

Parkinsonism & related disorders

Pub Date : 2025-02-21 DOI: 10.1016/j.parkreldis.2025.107347

Eric R Cole, Svjetlana Miocinovic

Deep brain stimulation (DBS) requires individualized programming of stimulation parameters, a time-consuming process performed manually by clinicians with specialized training. This process limits DBS accessibility, delays treatment, and constrains the potential for next-generation technology to improve patient outcomes. This review describes technological advancements that could automate DBS programming, focusing on Parkinson's disease biomarkers that can provide objective outcome measurement and algorithms that can quickly and automatically identify optimal DBS settings. We first define key performance criteria for an automated programming system, including effectiveness, efficiency, and ease of use, and then describe and evaluate each component with respect to these criteria. We conclude that the state of current research provides a strong foundation for developing automated DBS programming. The primary remaining obstacle lies in identifying and deploying the best combination of available techniques that will overcome the high entry barrier needed for wide-scale clinical deployment and adoption.

引用次数: 0

Can we detect cognitive “super-agers” in Parkinson's disease? Cognitive, neuropsychiatric and motor outcomes in the first 10 years of Parkinson's disease

IF 3.1 3区医学 Q2 CLINICAL NEUROLOGY

Parkinsonism & related disorders

Pub Date : 2025-02-21 DOI: 10.1016/j.parkreldis.2025.107345

Ruth Uribe-Kirby , Alejandra Pawlak , Lauren Pitman , Gwenevere Zuniga , Jacob D. Jones

Introduction

Superagers are older individuals who resist age-related cognitive decline and who perform just as well or better than younger people in cognitive tasks. In healthy aging studies, superagers not only experience positive cognitive outcomes (e.g. lower risk of future mild cognitive impairment), but may also experience fewer depressive and anxiety symptoms as they age. We seek to identify superagers in Parkinson's disease (PD) and potential outcomes associated with superager status.

Methods

Data was gathered from the Parkinson's Progression Markers Initiative (PPMI). 689 individuals newly diagnosed with PD were assessed annually for up to 10 years. Participants were classified into three groups: superagers, cognitively normal, and PD mild cognitive impairment (PD-MCI). Multilevel models examined longitudinal group differences in global cognition, depression, anxiety, and motor severity.

Results

A significant main effect of group revealed that superagers performed better than the PD-MCI and cognitively normal groups in global cognition. There were significant group by time interactions, revealing the superagers group was on a more favorable longitudinal trajectory relative to other two groups. Superagers also reported less severe depressive and anxiety symptoms compared to the PD-MCI and the cognitively normal groups. Superagers had a more favorable trajectory of motor symptom severity relative to the cognitively normal and PD-MCI groups.

Conclusion

Superagers with PD may be detected with neuropsychological testing and appear to resist the effects of neurodegeneration in Parkinson's disease. Cognitive studies and trials may benefit from incorporating the concept of superagers, as opposed to a single homogenous cognitively normal group.

{"title":"Can we detect cognitive “super-agers” in Parkinson's disease? Cognitive, neuropsychiatric and motor outcomes in the first 10 years of Parkinson's disease","authors":"Ruth Uribe-Kirby , Alejandra Pawlak , Lauren Pitman , Gwenevere Zuniga , Jacob D. Jones","doi":"10.1016/j.parkreldis.2025.107345","DOIUrl":"10.1016/j.parkreldis.2025.107345","url":null,"abstract":"<div><h3>Introduction</h3><div>Superagers are older individuals who resist age-related cognitive decline and who perform just as well or better than younger people in cognitive tasks. In healthy aging studies, superagers not only experience positive cognitive outcomes (e.g. lower risk of future mild cognitive impairment), but may also experience fewer depressive and anxiety symptoms as they age. We seek to identify superagers in Parkinson's disease (PD) and potential outcomes associated with superager status.</div></div><div><h3>Methods</h3><div>Data was gathered from the Parkinson's Progression Markers Initiative (PPMI). 689 individuals newly diagnosed with PD were assessed annually for up to 10 years. Participants were classified into three groups: superagers, cognitively normal, and PD mild cognitive impairment (PD-MCI). Multilevel models examined longitudinal group differences in global cognition, depression, anxiety, and motor severity.</div></div><div><h3>Results</h3><div>A significant main effect of group revealed that superagers performed better than the PD-MCI and cognitively normal groups in global cognition. There were significant group by time interactions, revealing the superagers group was on a more favorable longitudinal trajectory relative to other two groups. Superagers also reported less severe depressive and anxiety symptoms compared to the PD-MCI and the cognitively normal groups. Superagers had a more favorable trajectory of motor symptom severity relative to the cognitively normal and PD-MCI groups.</div></div><div><h3>Conclusion</h3><div>Superagers with PD may be detected with neuropsychological testing and appear to resist the effects of neurodegeneration in Parkinson's disease. Cognitive studies and trials may benefit from incorporating the concept of superagers, as opposed to a single homogenous cognitively normal group.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"133 ","pages":"Article 107345"},"PeriodicalIF":3.1,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143488465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Daily variation in symptoms and functioning in Huntington disease: Feasibility and variability

IF 3.1 3区医学 Q2 CLINICAL NEUROLOGY

Parkinsonism & related disorders

Pub Date : 2025-02-21 DOI: 10.1016/j.parkreldis.2025.107346

Noelle E. Carlozzi , Jonathan P. Troost , Jennifer A. Miner , Karandeep Singh , Arjun A. Padmanabhan , Wendy L. Lombard , Praveen Dayalu

Introduction

The day-to-day experience of symptoms and functioning are largely understudied in people with Huntington disease (HD). Real-world capture of day-to-day symptoms and functioning could be valuable as future HD outcome measures. Therefore, the purpose of this study was to 1) examine the feasibility of a weeklong intensive study design; and 2) understand the daily variation of symptoms and functioning in individuals with premanifest and manifest HD.

Methods

During this 8-day study, 52 individuals with HD completed real-time symptom reports 3 times each day (chorea, sleep, fatigue, anxiety), wore a wrist-worn device (PRO-Diary sleep and physical activity), and completed daily diaries of symptoms (chorea, sleep, fatigue, anger, depression, anxiety) and functioning (physical activity, speech/swallowing, and social participation) each night. We examined rates of missing data, and multilevel models were used to analyze data.

Results

Rates of missing data were 23–52 % for the real-time symptom reports and 19–35 % for the daily diaries. Average PRO-Diary wear compliance was 64 % for manifest and 67 % for pre-manifest HD for sleep, and 71 % for pre-manifest and 78 % for manifest HD for physical activity. Within-subject variability was greater over the week (day-to-day median range 1.9–4.4 SDs) than over the day (within-a-day median range 0–2 SDs). Associations between baseline and real-time reports of the same constructs were generally consistent.

Conclusions

Rates of missing data were consistent with similar study designs in other clinical populations, supporting feasibility. Missingness was highest for the real-time symptom reports. HD participants experienced more day-to-day variation in symptoms and function, with less variability within a day, suggesting that once-daily assessments may suffice.

{"title":"Daily variation in symptoms and functioning in Huntington disease: Feasibility and variability","authors":"Noelle E. Carlozzi , Jonathan P. Troost , Jennifer A. Miner , Karandeep Singh , Arjun A. Padmanabhan , Wendy L. Lombard , Praveen Dayalu","doi":"10.1016/j.parkreldis.2025.107346","DOIUrl":"10.1016/j.parkreldis.2025.107346","url":null,"abstract":"<div><h3>Introduction</h3><div>The day-to-day experience of symptoms and functioning are largely understudied in people with Huntington disease (HD). Real-world capture of day-to-day symptoms and functioning could be valuable as future HD outcome measures. Therefore, the purpose of this study was to 1) examine the feasibility of a weeklong intensive study design; and 2) understand the daily variation of symptoms and functioning in individuals with premanifest and manifest HD.</div></div><div><h3>Methods</h3><div>During this 8-day study, 52 individuals with HD completed real-time symptom reports 3 times each day (chorea, sleep, fatigue, anxiety), wore a wrist-worn device (PRO-Diary sleep and physical activity), and completed daily diaries of symptoms (chorea, sleep, fatigue, anger, depression, anxiety) and functioning (physical activity, speech/swallowing, and social participation) each night. We examined rates of missing data, and multilevel models were used to analyze data.</div></div><div><h3>Results</h3><div>Rates of missing data were 23–52 % for the real-time symptom reports and 19–35 % for the daily diaries. Average PRO-Diary wear compliance was 64 % for manifest and 67 % for pre-manifest HD for sleep, and 71 % for pre-manifest and 78 % for manifest HD for physical activity. Within-subject variability was greater over the week (day-to-day median range 1.9–4.4 SDs) than over the day (within-a-day median range 0–2 SDs). Associations between baseline and real-time reports of the same constructs were generally consistent.</div></div><div><h3>Conclusions</h3><div>Rates of missing data were consistent with similar study designs in other clinical populations, supporting feasibility. Missingness was highest for the real-time symptom reports. HD participants experienced more day-to-day variation in symptoms and function, with less variability within a day, suggesting that once-daily assessments may suffice.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"133 ","pages":"Article 107346"},"PeriodicalIF":3.1,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143518859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case series of nine patients with cerebrotendinous xanthomatosis from India and a systematized review of Indian literature

IF 3.1 3区医学 Q2 CLINICAL NEUROLOGY

Parkinsonism & related disorders

Pub Date : 2025-02-15 DOI: 10.1016/j.parkreldis.2025.107331

Farsana Mustafa , Thrupthi Km , Ayush Agarwal , Jacky Ganguly , Suvorit Subhas Bhowmick , Ajay Garg , Shariq Ahmad Shah , Hrishikesh Kumar , Soutrik Das , Achal Kumar Srivastava , Shailesh B. Gaikwad , Divyani Garg

Introduction

Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive congenital disorder of bile acid metabolism resulting from variants in the CYP27A1 gene. CTX presents with heterogenous clinical features. Descriptions from diverse populations remain sparse, particularly from the Indian subcontinent.

Methods

We report a case series of nine Indian patients with CTX, accompanied by a systematized review of Indian literature.

Results

Our case series revealed inter- and intrafamilial heterogeneity. Our review of 36 published cases revealed that most Indian patients presented with neurobehavioral syndromes and spastic ataxia, and parkinsonism and dystonia were considerably rare; 34/36 cases eventually developed cataract, usually in childhood, which was a ‘tell-tale’ sign. Radiological findings revealed striking dentate T2/FLAIR hyperintensities, periventricular white matter involvement, and involvement of the corticospinal tract, and could detect clinically invisible tendon xanthomas. Missense and frameshift truncation variants were most common in the Indian literature, with the c.525delG variant being encountered most frequently. Several patients received a clinico-radiological/histopathological diagnosis as genetic testing was not performed in all patients. Most patients received ursodeoxycholic acid although it is ineffective in the treatment of CTX.

Conclusion

CTX is a not-to-be-missed treatable ataxia syndrome with heterogeneous clinical features. Parkinsonism and dystonia seem to be less prevalent in Indian cases compared to world literature. Our review also highlights the difficulty in access to, availability of and the urgent need to provide chenodeoxycholic acid in our region, reflected in the small fraction of patients who received this definite treatment despite the ‘reversible’ nature of the disease.

{"title":"A case series of nine patients with cerebrotendinous xanthomatosis from India and a systematized review of Indian literature","authors":"Farsana Mustafa , Thrupthi Km , Ayush Agarwal , Jacky Ganguly , Suvorit Subhas Bhowmick , Ajay Garg , Shariq Ahmad Shah , Hrishikesh Kumar , Soutrik Das , Achal Kumar Srivastava , Shailesh B. Gaikwad , Divyani Garg","doi":"10.1016/j.parkreldis.2025.107331","DOIUrl":"10.1016/j.parkreldis.2025.107331","url":null,"abstract":"<div><h3>Introduction</h3><div>Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive congenital disorder of bile acid metabolism resulting from variants in the <em>CYP27A1</em> gene. CTX presents with heterogenous clinical features. Descriptions from diverse populations remain sparse, particularly from the Indian subcontinent.</div></div><div><h3>Methods</h3><div>We report a case series of nine Indian patients with CTX, accompanied by a systematized review of Indian literature.</div></div><div><h3>Results</h3><div>Our case series revealed inter- and intrafamilial heterogeneity. Our review of 36 published cases revealed that most Indian patients presented with neurobehavioral syndromes and spastic ataxia, and parkinsonism and dystonia were considerably rare; 34/36 cases eventually developed cataract, usually in childhood, which was a ‘tell-tale’ sign. Radiological findings revealed striking dentate T2/FLAIR hyperintensities, periventricular white matter involvement, and involvement of the corticospinal tract, and could detect clinically invisible tendon xanthomas. Missense and frameshift truncation variants were most common in the Indian literature, with the c.525delG variant being encountered most frequently. Several patients received a clinico-radiological/histopathological diagnosis as genetic testing was not performed in all patients. Most patients received ursodeoxycholic acid although it is ineffective in the treatment of CTX.</div></div><div><h3>Conclusion</h3><div>CTX is a not-to-be-missed treatable ataxia syndrome with heterogeneous clinical features. Parkinsonism and dystonia seem to be less prevalent in Indian cases compared to world literature. Our review also highlights the difficulty in access to, availability of and the urgent need to provide chenodeoxycholic acid in our region, reflected in the small fraction of patients who received this definite treatment despite the ‘reversible’ nature of the disease.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"133 ","pages":"Article 107331"},"PeriodicalIF":3.1,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143453847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Waking up to the role of sleep disturbances in freezing of gait among people with Parkinson's disease. 醒悟睡眠障碍在帕金森病患者步态冻结中的作用。

IF 3.1 3区医学 Q2 CLINICAL NEUROLOGY

Parkinsonism & related disorders

Pub Date : 2025-02-15 DOI: 10.1016/j.parkreldis.2025.107342

Jennifer Zitser, Talia Herman, Nir Giladi, Jeffrey M Hausdorff

引用次数: 0

Convergence insufficiency and Parkinson's disease progression

IF 3.1 3区医学 Q2 CLINICAL NEUROLOGY

Parkinsonism & related disorders

Pub Date : 2025-02-15 DOI: 10.1016/j.parkreldis.2025.107341

Alba Herrero-Gracia , Rosa Hernández-Andrés , María José Luque , Kenneth J. Ciuffreda , M Amparo Díez-Ajenjo

Background

Parkinson's disease (PD) is a chronic, neurodegenerative disorder that significantly affects motor, sensory, and vision functions. Convergence insufficiency (CI) may be an indicator of PD progression. This study aimed to explore the relationship between CI and the stages of PD progression, as measured by the Hoehn and Yahr scale, and to compare the prevalence of CI and vision parameters between healthy individuals and PD patients.

Methods

Age-matched healthy controls (n = 97) and PD patients (n = 71) underwent medical history evaluations and vision assessments. Statistical analyses were conducted to compare CI prevalence across the Hoehn and Yahr stages between the control and PD groups. Binary logistic regression was used to evaluate the increase in CI prevalence as PD stages advanced.

Results

Significant differences in CI prevalence were noted between the control group (CG) and the PD group (PG), particularly in Stage III (p < .001) and overall (p < .001). The prevalence of CI increased with advancing PD stages (p < .001). In Stage I, CI emerged as the only significant factor, while Stages II and III revealed significant differences in multiple vergence-related parameters. Logistic regression revealed increased odds of CI correlating with advancing Hoehn and Yahr stages (p < .007).

Conclusion

A significant association was found between CI and PD progression. These findings underscore the importance of standardized assessment methods and the need for longitudinal research. Regular vision evaluations are essential for effectively managing CI and related vergence deficits in patients with PD.

{"title":"Convergence insufficiency and Parkinson's disease progression","authors":"Alba Herrero-Gracia , Rosa Hernández-Andrés , María José Luque , Kenneth J. Ciuffreda , M Amparo Díez-Ajenjo","doi":"10.1016/j.parkreldis.2025.107341","DOIUrl":"10.1016/j.parkreldis.2025.107341","url":null,"abstract":"<div><h3>Background</h3><div>Parkinson's disease (PD) is a chronic, neurodegenerative disorder that significantly affects motor, sensory, and vision functions. Convergence insufficiency (CI) may be an indicator of PD progression. This study aimed to explore the relationship between CI and the stages of PD progression, as measured by the Hoehn and Yahr scale, and to compare the prevalence of CI and vision parameters between healthy individuals and PD patients.</div></div><div><h3>Methods</h3><div>Age-matched healthy controls (n = 97) and PD patients (n = 71) underwent medical history evaluations and vision assessments. Statistical analyses were conducted to compare CI prevalence across the Hoehn and Yahr stages between the control and PD groups. Binary logistic regression was used to evaluate the increase in CI prevalence as PD stages advanced.</div></div><div><h3>Results</h3><div>Significant differences in CI prevalence were noted between the control group (CG) and the PD group (PG), particularly in Stage III (p < .001) and overall (p < .001). The prevalence of CI increased with advancing PD stages (p < .001). In Stage I, CI emerged as the only significant factor, while Stages II and III revealed significant differences in multiple vergence-related parameters. Logistic regression revealed increased odds of CI correlating with advancing Hoehn and Yahr stages (p < .007).</div></div><div><h3>Conclusion</h3><div>A significant association was found between CI and PD progression. These findings underscore the importance of standardized assessment methods and the need for longitudinal research. Regular vision evaluations are essential for effectively managing CI and related vergence deficits in patients with PD.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"133 ","pages":"Article 107341"},"PeriodicalIF":3.1,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143436848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Parkinsonism & related disorders

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀